Autonomix Medical, Inc. Common Stock(AMIX)Earnings, Financials & Key Ratios
AMIX•NASDAQ
$0.38
$679733 mkt cap·Price updated May 6, 2026
AboutAutonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.Show more
- Revenue$0
- EBITDA-$11M+4.6%
- Net Income-$11M+26.0%
- EPS (Diluted)-6.46+69.4%
- ROE-145.1%+61.1%
- Interest Coverage-65.84+56.8%
AMIX Key Insights
Autonomix Medical, Inc. Common Stock (AMIX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 8 (bottom 8%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
AMIX Price & Volume
Autonomix Medical, Inc. Common Stock (AMIX) stock price & volume — 10-year historical chart
Loading chart...
AMIX Growth Metrics
Autonomix Medical, Inc. Common Stock (AMIX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-26.52%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-5.96%
Return on Capital
10 Years-311.15%
5 Years-311.15%
3 Years-183.61%
Last Year-138.54%
AMIX Peer Comparison
Autonomix Medical, Inc. Common Stock (AMIX) competitors in Neuromodulation and neuro devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 BSX | 83.23B | 56.00 | 28.87 | 19.87% | 14.4% | 12.4% | 0.51 | |
 MDT | 99.48B | 77.60 | 21.50 | 3.62% | 13% | 9.45% | 0.59 | |
 ABT | 149.97B | 86.25 | 11.29 | 4.59% | 31.88% | 27.26% | 0.32 | |
 SYK | 111.96B | 292.33 | 34.80 | 11.16% | 12.92% | 15.04% | 0.66 | |
 ISRG | 160.44B | 451.73 | 57.40 | 20.51% | 28.15% | 16.89% | 0.02 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 10.37% | 0.52 | |
 MMSI | 3.68B | 61.63 | 28.93 | 11.66% | 9.03% | 8.95% | 0.57 |
Compare AMIX vs Peers
Autonomix Medical, Inc. Common Stock (AMIX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AMIX Income Statement
Autonomix Medical, Inc. Common Stock (AMIX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 54K |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -54K▲ 0% |
| Gross Margin % | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - |
| Operating Expenses | 13.59M | 1.99M | 12.03M | 11.59M | 17.5M |
| OpEx % of Revenue | - | - | - | - | - |
| Selling, General & Admin | 13.59M | 1.25M | 5.25M | 6.86M | 10.26M |
| SG&A % of Revenue | - | - | - | - | - |
| Research & Development | 4.07K | 745K | 2.23M | 4.72M | 7.24M |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 4.56M | 0 | 0 |
| Operating Income | -13.59M▲ 0% | -1.99M▲ 85.4% | -12.03M▼ 504.5% | -11.59M▲ 3.7% | -17.55M▲ 0% |
| Operating Margin % | - | - | - | - | - |
| Operating Income Growth % | - | 85.36% | -504.52% | 3.67% | - |
| EBITDA | 0 | -1.99M | -11.95M | -11.4M | -17.49M |
| EBITDA Margin % | - | - | - | - | - |
| EBITDA Growth % | - | - | -500.45% | 4.55% | -65.48% |
| D&A (Non-Cash Add-back) | 13.59M | 0 | 81K | 183K | 57K |
| EBIT | -13.59M | -1.99M | -15.35M | -11.23M | -17.28M |
| Net Interest Income | -218.09K | 0 | 48K | 178K | 310K |
| Interest Income | 0 | 0 | 127K | 354K | 356K |
| Interest Expense | 218.09K | 0 | 79K | 176K | 46K |
| Other Income/Expense | 265.56K | 0 | -3.4M | 178K | 310K |
| Pretax Income | -13.33M▲ 0% | -1.99M▲ 85.1% | -15.43M▼ 675.2% | -11.41M▲ 26.0% | -17.24M▲ 0% |
| Pretax Margin % | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
| Net Income | -13.33M▲ 0% | -1.99M▲ 85.1% | -15.43M▼ 675.2% | -11.41M▲ 26.0% | -17.24M▲ 0% |
| Net Margin % | - | - | - | - | - |
| Net Income Growth % | - | 85.07% | -675.18% | 26.03% | -26.52% |
| Net Income (Continuing) | -13.33M | -1.99M | -15.43M | -11.41M | -17.24M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.71▲ 0% | -0.11▲ 84.5% | -21.09▼ 19072.7% | -6.46▲ 69.4% | -1.93▲ 0% |
| EPS Growth % | - | 84.51% | -19072.73% | 69.37% | -5.96% |
| EPS (Basic) | -0.71 | -0.11 | -21.10 | -6.46 | - |
| Diluted Shares Outstanding | 18.79M | 18.79M | 731.31K | 1.77M | 8.96M |
| Basic Shares Outstanding | 18.79M | 18.79M | 731K | 1.77M | 8.96M |
| Dividend Payout Ratio | - | - | - | - | - |
AMIX Balance Sheet
Autonomix Medical, Inc. Common Stock (AMIX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|
| Total Current Assets | 2.05M | 865K | 9.39M | 9.61M | 10.19M |
| Cash & Short-Term Investments | 2.04M | 865K | 8.61M | 9.14M | 9.93M |
| Cash Only | 2.04M | 865K | 8.61M | 9.14M | 9.93M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 8.73K | 0 | 783K | 473K | 257K |
| Total Non-Current Assets | 0 | 0 | 16K | 197K | 20K |
| Property, Plant & Equipment | 0 | 0 | 16K | 21K | 20K |
| Fixed Asset Turnover | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 176K | 199K |
| Total Assets | 2.05M▲ 0% | 865K▼ 57.9% | 9.41M▲ 987.5% | 9.81M▲ 4.2% | 10.21M▲ 0% |
| Asset Turnover | - | - | - | - | 0.00x |
| Asset Growth % | - | -57.86% | 987.51% | 4.24% | 64.16% |
| Total Current Liabilities | 93.24K | 221K | 777K | 1.71M | 1.65M |
| Accounts Payable | 91.62K | 173K | 492K | 676K | 714K |
| Days Payables Outstanding | - | - | - | - | 5.15K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.62K | 0 | 0 | 0 | 1.65M |
| Current Ratio | 22.02x | 3.91x | 12.09x | 5.63x | 5.63x |
| Quick Ratio | 22.02x | 3.91x | 12.09x | 5.63x | 5.63x |
| Cash Conversion Cycle | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 1M | 0 | 0 |
| Long-Term Debt | 0 | 0 | 1M | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 93.24K | 221K | 1.78M | 1.71M | 1.65M |
| Total Debt | 0 | 0 | 1M | 0 | 0 |
| Net Debt | -2.04M | -865K | -7.61M | -9.14M | -9.93M |
| Debt / Equity | - | - | 0.13x | - | 0.00x |
| Debt / EBITDA | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | 0.57x |
| Interest Coverage | -62.33x | - | -152.28x | -65.84x | -375.57x |
| Total Equity | 1.96M▲ 0% | 644K▼ 67.1% | 7.63M▲ 1084.5% | 8.1M▲ 6.2% | 8.56M▲ 0% |
| Equity Growth % | - | -67.13% | 1084.47% | 6.17% | 140.17% |
| Book Value per Share | 0.10 | 0.03 | 10.43 | 4.59 | 0.96 |
| Total Shareholders' Equity | 1.96M | 644K | 7.63M | 8.1M | 8.56M |
| Common Stock | 12K | 12K | 19K | 2K | 11K |
| Retained Earnings | -21.55M | -23.54M | -38.97M | -50.38M | -64.43M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
AMIX Cash Flow Statement
Autonomix Medical, Inc. Common Stock (AMIX) cash flow — operating, investing & free cash flow history
| Line item | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|
| Cash from Operations | -387.31K | -1.85M | -6.65M | -8.26M | -8.26M |
| Operating CF Margin % | - | - | - | - | - |
| Operating CF Growth % | - | -378.79% | -258.5% | -24.22% | -184.87% |
| Net Income | -13.33M | -1.99M | -15.43M | -11.41M | -17.24M |
| Depreciation & Amortization | 0 | 0 | 81K | 183K | 57K |
| Stock-Based Compensation | 0 | 0 | 618 | 1.63M | 933K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 12.74M | 0 | 8.62M | 101K | 4.12M |
| Working Capital Changes | 204.41K | 136.08K | 79K | 1.24M | 229K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 87.08K | 80.91K | 320K | 184K | 447K |
| Cash from Investing | 0 | 0 | -19K | -14K | -11K |
| Capital Expenditures | 0 | 0 | -19K | -14K | -11K |
| CapEx % of Revenue | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 2.43M | 675K | 14.41M | 8.8M | 10.02M |
| Debt Issued (Net) | 536K | 0 | 2M | 0 | 0 |
| Equity Issued (Net) | 1000K | 675K | 1000K | 1000K | 2M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | -1.3M | -1.23M | 5.78M |
| Net Change in Cash | 2.04M▲ 0% | -1.18M▼ 157.7% | 7.74M▲ 756.5% | 528K▼ 93.2% | -2.44M▲ 0% |
| Free Cash Flow | -387.31K▲ 0% | -1.85M▼ 378.8% | -6.67M▼ 259.5% | -8.27M▼ 24.1% | -11.91M▲ 0% |
| FCF Margin % | - | - | - | - | - |
| FCF Growth % | - | -378.79% | -259.52% | -24.07% | -42.95% |
| FCF per Share | -0.02 | -0.10 | -9.12 | -4.68 | -4.68 |
| FCF Conversion (FCF/Net Income) | 0.03x | 0.93x | 0.43x | 0.72x | 0.69x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
AMIX Key Ratios
Autonomix Medical, Inc. Common Stock (AMIX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|
| Return on Equity (ROE) | -152.87% | -372.97% | -145.1% | -201.38% |
| Return on Invested Capital (ROIC) | - | - | - | 1053.21% |
| Debt / Equity | - | 0.13x | - | 0.00x |
| Interest Coverage | - | -152.28x | -65.84x | -375.57x |
| FCF Conversion | 0.93x | 0.43x | 0.72x | 0.69x |
AMIX Frequently Asked Questions
Autonomix Medical, Inc. Common Stock (AMIX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Autonomix Medical, Inc. Common Stock (AMIX) grew revenue by 0.0% over the past year. Growth has been modest.
Autonomix Medical, Inc. Common Stock (AMIX) reported a net loss of $17.2M for fiscal year 2025.
Dividend & Returns
Autonomix Medical, Inc. Common Stock (AMIX) has a return on equity (ROE) of -145.1%. Negative ROE indicates the company is unprofitable.
Autonomix Medical, Inc. Common Stock (AMIX) had negative free cash flow of $11.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More AMIX
Autonomix Medical, Inc. Common Stock (AMIX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates